1. Home
  2. ICCM vs IFRX Comparison

ICCM vs IFRX Comparison

Compare ICCM & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IceCure Medical Ltd.

ICCM

IceCure Medical Ltd.

HOLD

Current Price

$0.61

Market Cap

43.4M

Sector

N/A

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$0.91

Market Cap

60.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICCM
IFRX
Founded
2006
2007
Country
Israel
Germany
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
43.4M
60.6M
IPO Year
2013
2017

Fundamental Metrics

Financial Performance
Metric
ICCM
IFRX
Price
$0.61
$0.91
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$2.50
$8.50
AVG Volume (30 Days)
169.8K
274.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$19.87
N/A
Revenue Next Year
$31.38
$1,054.36
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.54
$0.71
52 Week High
$1.53
$1.94

Technical Indicators

Market Signals
Indicator
ICCM
IFRX
Relative Strength Index (RSI) 56.27 46.47
Support Level $0.59 $0.81
Resistance Level $0.74 $0.91
Average True Range (ATR) 0.03 0.05
MACD 0.01 0.01
Stochastic Oscillator 78.41 54.63

Price Performance

Historical Comparison
ICCM
IFRX

About ICCM IceCure Medical Ltd.

Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: